Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

Alzheimer’s disease market set to double to $10.4 Billion by 2021

February 11, 2016 Research and Development, Sales and Marketing Alzheimer's disease

The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
News
msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016 Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
News

Novartis says CDF proposals place “unreasonable” risk on pharma

February 10, 2016 Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis

Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
News

FDA advisory committee recommends approval of Remicade biosimilar

February 10, 2016 Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion

An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
News
albert_bourla

Pfizer names leadership team post-Allergan merger

February 9, 2016 Manufacturing and Production, Sales and Marketing Allergan, Pfizer

Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …
Appointment
fda

FDA set to approve Remicade biosimilar

February 9, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima

An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
News

NICE changes mind on Amgen’s cholesterol drug

February 8, 2016 Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha

NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
News
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016 Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
News
jeremy_hunt_appears_on_thye_bbcs_andrew_marr_show_february_7

UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision

February 8, 2016 Medical Communications, Sales and Marketing Jeremy Hunt, NHS

UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …
News
shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
News
Lundbeck HQ

Lundbeck gets go-ahead for US and EU licence expansions

February 4, 2016 Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine

Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
News
astrazeneca_plaque

AZ warns of patent losses as revenues fall

February 4, 2016 Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic

AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
News
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016 Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
News
Merck image

Revenues down at MSD

February 4, 2016 Sales and Marketing MSD, financial performance, profits, revenue, sales

MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …
News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026